company background image
NOVO B logo

Novo Nordisk CPSE:NOVO B Stock Report

Last Price

kr.991.00

Market Cap

kr.4.4t

7D

0.7%

1Y

79.6%

Updated

14 Jun, 2024

Data

Company Financials +

NOVO B Stock Overview

Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

NOVO B fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance5/6
Financial Health4/6
Dividends0/6

Novo Nordisk A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Pricekr.991.00
52 Week Highkr.997.40
52 Week Lowkr.504.40
Beta0.17
1 Month Change8.06%
3 Month Change9.62%
1 Year Change79.56%
3 Year Change285.23%
5 Year Change495.28%
Change since IPO36,671.81%

Recent News & Updates

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jun 09
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04
Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

Recent updates

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jun 09
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04
Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Apr 28
The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Mar 18
Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Dec 30
Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Dec 12
Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Nov 24
Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Aug 20
Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Shareholder Returns

NOVO BDK PharmaceuticalsDK Market
7D0.7%0.03%-0.6%
1Y79.6%18.5%36.3%

Return vs Industry: NOVO B exceeded the Danish Pharmaceuticals industry which returned 18.5% over the past year.

Return vs Market: NOVO B exceeded the Danish Market which returned 36.3% over the past year.

Price Volatility

Is NOVO B's price volatile compared to industry and market?
NOVO B volatility
NOVO B Average Weekly Movement3.2%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement4.4%
10% most volatile stocks in DK Market10.2%
10% least volatile stocks in DK Market2.8%

Stable Share Price: NOVO B has not had significant price volatility in the past 3 months.

Volatility Over Time: NOVO B's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192366,015Lars Jorgensenwww.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVO B fundamental statistics
Market capkr.4.40t
Earnings (TTM)kr.89.28b
Revenue (TTM)kr.244.24b

49.2x

P/E Ratio

18.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVO B income statement (TTM)
Revenuekr.244.24b
Cost of Revenuekr.37.50b
Gross Profitkr.206.74b
Other Expenseskr.117.47b
Earningskr.89.28b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 07, 2024

Earnings per share (EPS)20.13
Gross Margin84.65%
Net Profit Margin36.55%
Debt/Equity Ratio27.2%

How did NOVO B perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

50%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.